Ballentine Partners’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $350K | Buy |
4,070
+560
| +16% | +$49.1K | ﹤0.01% | 714 |
|
|
2026
Q1 | $317K | Buy |
3,510
+162
| +5% | +$14.9K | ﹤0.01% | 711 |
|
|
2025
Q4 | $301K | Sell |
3,348
-51
| -2% | -$4.84K | ﹤0.01% | 721 |
|
|
2025
Q3 | $335K | Sell |
3,399
-249
| -7% | -$24.7K | ﹤0.01% | 668 |
|
|
2025
Q2 | $333K | Sell |
3,648
-140
| -4% | -$13.5K | 0.01% | 651 |
|
|
2025
Q1 | $429K | Sell |
3,788
-783
| -17% | -$83.8K | 0.01% | 494 |
|
|
2024
Q4 | $483K | Buy |
4,571
+716
| +19% | +$76.8K | 0.01% | 434 |
|
|
2024
Q3 | $416K | Buy |
3,855
+73
| +2% | +$7.97K | 0.01% | 473 |
|
|
2024
Q2 | $410K | Sell |
3,782
-175
| -4% | -$20.6K | 0.01% | 451 |
|
|
2024
Q1 | $522K | Buy |
3,957
+100
| +3% | +$12.5K | 0.01% | 378 |
|
|
2023
Q4 | $469K | Buy |
3,857
+41
| +1% | +$4.58K | 0.01% | 383 |
|
|
2023
Q3 | $428K | Sell |
3,816
-3
| -0.1% | -$381 | 0.01% | 347 |
|
|
2023
Q2 | $556K | Sell |
3,819
-320
| -8% | -$43.5K | 0.01% | 291 |
|
|
2023
Q1 | $535K | Buy |
4,139
+7
| +0.2% | +$879 | 0.01% | 288 |
|
|
2022
Q4 | $527K | Buy |
4,132
+2
| +0% | +$232 | 0.02% | 269 |
|
|
2022
Q3 | $432K | Buy |
4,130
+217
| +6% | +$23.8K | 0.01% | 270 |
|
|
2022
Q2 | $412K | Sell |
3,913
-103
| -3% | -$12.2K | 0.01% | 264 |
|
|
2022
Q1 | $513K | Buy |
4,016
+221
| +6% | +$26.6K | 0.02% | 253 |
|
|
2021
Q4 | $468K | Buy |
3,795
+58
| +2% | +$7.59K | 0.01% | 282 |
|
|
2021
Q3 | $531K | Buy |
3,737
+4
| +0.1% | +$588 | 0.02% | 228 |
|
|
2021
Q2 | $583K | Buy |
3,733
+1,215
| +48% | +$197K | 0.02% | 214 |
|
|
2021
Q1 | $391K | Sell |
2,518
-60
| -2% | -$9.29K | 0.01% | 260 |
|
|
2020
Q4 | $386K | Hold |
2,578
| – | – | 0.02% | 244 |
|
|
2020
Q3 | $340K | Buy |
2,578
+4
| +0.2% | +$523 | 0.02% | 271 |
|
|
2020
Q2 | $299K | Buy |
2,574
+28
| +1% | +$3.23K | 0.01% | 278 |
|
|
2020
Q1 | $251K | Sell |
2,546
-156
| -6% | -$20.4K | 0.01% | 280 |
|
|
2019
Q4 | $393K | Buy |
2,702
+34
| +1% | +$4.69K | 0.02% | 252 |
|
|
2019
Q3 | $355K | Buy |
2,668
+232
| +10% | +$30K | 0.02% | 258 |
|
|
2019
Q2 | $278K | Buy |
2,436
+202
| +9% | +$23.7K | 0.01% | 305 |
|
|
2019
Q1 | $277K | Sell |
2,234
-17
| -0.8% | -$1.93K | 0.01% | 256 |
|
|
2018
Q4 | $227K | Buy |
+2,251
| New | +$253K | 0.01% | 284 |
|
Other funds holding ZBH
Ballentine Partners's ZBH Position: Q2 2026 in Review
Ballentine Partners increased its Zimmer Biomet (ZBH) stake by 16% in Q2 2026, buying an estimated $49.1K and bringing the position to 4,070 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #714.
Ballentine Partners first reported a position in ZBH in Q4 2018 and has held it in 31 quarters since. The position peaked at $583K in Q2 2021. 909 funds tracked by Wall St. Rank hold ZBH as of Q2 2026.
- Ballentine Partners held 4,070 shares of Zimmer Biomet worth $350K as of Q2 2026.
- Ballentine Partners bought 560 Zimmer Biomet shares in Q2 2026, an estimated $49.1K.
- Zimmer Biomet made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #714 holding.
- Ballentine Partners first reported a position in Zimmer Biomet in Q4 2018 and has held it in 31 quarters since.
- Ballentine Partners's Zimmer Biomet position peaked at $583K in Q2 2021.
- 909 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2026.
Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.